alexa Application of PBPK Models in Personalized Healthcare | OMICS International
Journal of Pharmacokinetics & Experimental Therapeutics
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Application of PBPK Models in Personalized Healthcare

Randhir Singh Dahiya*

Department of Pharmacy, Maharishi Markandeshwar College of Pharmacy, MM University, Mullana, Haryana, India

*Corresponding Author:

Randhir Singh Dahiya
Department of Pharmacy
Maharishi Markandeshwar College of Pharmacy
MM University, Mullana, Haryana, India
Tel: 09896029234
E-mail: [email protected]

Received April 29, 2016; Accepted April 30, 2016; Published May 02, 2016

Citation: Dahiya RS (2016) Application of PBPK Models in Personalized Healthcare. J Pharmacokinet Exp Ther 1:e004. doi:10.4172/jpet.1000e004

Copyright: © 2016 Dahiya RS. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Pharmacokinetics & Experimental Therapeutics

Personalized Healthcare is known as customization of healthcare, where medical decisions, and/or products are being tailored to the individual patient need with focus on special population based on different physiological and disease conditions. Personalized healthcare is a paradigm that exists more in conceptual terms than in reality, with only a few marketed drug–test companion products and not very many actual clinical practices set up to personalize healthcare in the way that supporters have intended. In the past decades the main challenge is to manage the expectations of the medical community and the public at large that have already been set by speculation, and promises, to benefit the special populations, which includes pediatric, pregnancy, geriatric, and/or diseased conditions. These classes of populations were generally kept away from drug research to avoid potential harm, whereas the ratio of off-label prescription in these populations is high, ignoring lack of information. In recent years there is renewed surge of interests in the applications of Physiological based Pharmacokinetic Modeling and Simulations (PBPK M&S) by pharmaceutical industry and regulatory agencies. This research is focused on the application of Physiological based Pharmacokinetic Modeling and Simulations in personalized healthcare with emphasize on (1) pediatric populations (2) pregnant population, (3) population with special disease conditions including geriatric.

While the use of medications in these special populations is very common, efforts continue to focus on safe and efficacious dosing regimen along with information allowing patients and their physicians to make informed decisions about treatment on case-by-case basis. Thus, the drug use in special population is often not well justified due to lack of relevant studies. Recent regulatory guidelines from both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have mandated the drug developers to provide pediatric information for new drugs unless a waiver or deferral is accepted. A major challenge in drug development, with focus on special population, is determination of a safe and effective dose for each patient with specific age, physiology and diseased condition. The age, physiology and diseased condition of target population and the elimination pathway were the guidelines for choosing an appropriate modeling approach.

In the past decade, modeling and simulation approach along with physiologically based pharmacokinetics (PBPK) has become a powerful tool for designing and influence clinical trials and supporting regulatory interactions and approval, considering different challenges that are addressed with regard to clinical evidence. Ideally, whole-body PBPK models are used to simultaneously evaluate parameters that are systems-based and drug formulation-based and adjust for different physiological changes among special population on case-by-case basis. Different minimal PBPK models along with full PBPK model and mammillary model have been developed, with varying degree of success. Most importantly, minimal PBPK modeling provides a sensible modeling approach when fitting ONLY plasma (or blood) data but yielding physiologically-relevant PK parameters.

Consequently different methods in building pediatric and Pregnancy Pharmacokinetics (PK) models, using PBPK approach to address various safety and efficacy issues, related to sub-class of population are of utmost importance. The incorporation of known changes in physiology for example changes in renal, hepatic, gastrointestinal and cardiovascular physiology, along with the impact of transporter ontogeny on drug disposition among these special population, to predict the Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetic (PK) processes of different drugs can revolutionize the safety and efficacy of pharmacotherapy.

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Journals

Article Usage

  • Total views: 8699
  • [From(publication date):
    May-2016 - Aug 21, 2018]
  • Breakdown by view type
  • HTML page views : 8600
  • PDF downloads : 99
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

kactakapaniyor.com

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

Taktube

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

porn sex

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

Gaziantep Escort

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

sikiş

[email protected]

1-702-714-7001Extn: 9037

instafollowers

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

mp3 indir

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

putlockers

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

seks

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7